BALCAO · PHARMACEUTICAL PREPARATIONS
Pyrogenesis Canada Inc. PYRGF
4 fiscal years on record · CAD · FY2022 reported
SEC FILINGS ONLY
Revenue · FY2022
CAD 19.0M
▼ 38.8% vs FY2021
EPS · FY22
CAD -0.19
Dividend / sh · FY22
—
Payout · FY22
—
ROE · FY22
—
Net margin · FY22
-169.2%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
CAD 19.0M
Revenue, FY2022 · full 4-year series below
Revenue
Net income
The company lost 169 cents on every revenue dollar this year.
Per share
CAD -0.19
Diluted EPS, FY2022
EPS
The company pays no cash dividend.
Profitability
—
Return on equity, FY2022
ROE
Operating margin-122.0%
Net margin-169.2%
Return on assets-54.8%
Returned to shareholders
—
returned in FY2022 · dividends + net buybacks
Dividends paid—
Net buybacksCAD 0.00
Share of profit-0.0%
Consecutive raises—
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+58.1%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
—
Shares outstanding, FY2022
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
CAD 47.7M
total assets, end of FY2022
Total assetsCAD 47.7M
CashCAD 3.4M
Gross debtCAD 389,987.00
Net debtCAD -3.1M
Current ratio1.06×
History
4 fiscal years
Every figure from documents filed with the SEC · CAD
Metric
2022
2021
2020
2019
Revenue CAD B
0.0
0.0
0.0
0.0
Operating income CAD B
−0.0
−0.0
−0.0
−0.0
EBITDA CAD B
·
·
·
·
Income tax CAD B
0.0
−0.0
0.0
·
Net income CAD B
−0.0
−0.0
0.0
−0.0
EPS, diluted CAD
−0.19
−0.23
0.27
−0.07
Dividend / sh CAD
·
·
·
·
Payout %
·
·
·
·
ROE %
·
·
·
·
Shares out B
·
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
16 of 16
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed